Should intravenous immunoglobulin be used in infants with isoimmune haemolytic disease due to ABO incompatibility?
Date
2013
Authors
Keir, A.
Dunn, M.
Callum, J.
Editors
Advisors
Journal Title
Journal ISSN
Volume Title
Type:
Journal article
Citation
Journal of Paediatrics and Child Health, 2013; 49(12):1072-1078
Statement of Responsibility
Amy K Keir, Michael Dunn and Jeannie Callum
Conference Name
Abstract
The use of intravenous immunoglobulin in isoimmune haemolytic disease due to ABO incompatibility is recommended by the American Academy of Pediatrics and the National Blood Authority, Australia. However, the evidence these recommendations are based on appears limited and, in some instances, outdated. In our article, we review the current available literature to help answer the question, ‘In infants with isoimmune haemolytic disease due to ABO incompatibility [P], does use of intravenous immunoglobulin and intensive phototherapy [I] compared with intensive phototherapy alone [C] provide any clinically important benefits [O]?
School/Discipline
Dissertation Note
Provenance
Description
Access Status
Rights
© 2013 The Authors